Abstracts are available online at https://abstracts.asco.org/239/IndexView_239.html
6/1/2019 Pharma to Table
Levinson - Immunotherapy in Gyn Cancers
— Dee Sparacio (@womenofteal) June 1, 2019
— Dee Sparacio (@womenofteal) June 1, 2019
— Dee Sparacio (@womenofteal) June 1, 2019Rubin- Recognizing and Managing Immun-related Toxicities
irAE = immun-related Adverse Events
Events could include - cough, colitis, endocrine issues, pneumonitis
With adverse events is was recommended to not reduce the dose but rather hold the dose
Moore - Response Predictions and Signatures for ImmuntherapyRubin - combo therapies show more AES. These occur within 2-3 months of starting treatment #gyncsm #ASCO19 pic.twitter.com/WMRMiJTgPk— Dee Sparacio (@womenofteal) June 1, 2019
Tumor Burden is number of mutations in a tumor.
Dr Moore speaking on biomarkers in immunotherapy in gyn cancers . Many are in use and under study #gyncsm #ASCO19 pic.twitter.com/9DAW7XMiIx— Dee Sparacio (@womenofteal) June 1, 2019
Dorigo - The Future of Immunotherapy in Gyn CancersDr Moore’s conclusion slide. I learned that— Dee Sparacio (@womenofteal) June 1, 2019
Ovarian cancer has low tumor burden #ASCO19 #gyncsm pic.twitter.com/kDc298dgH1
TIL - Tumor Infiltrating Lymphocytes
Trials ongoing with HPV positive ovarian cancer ( yes , HPV can cause more than cervical and head and neck cancers. ) , CAR-T cells and vaccines
 |
| Trials like this one opening soon. |
Clinical Science Symposium
This session reviewed a number of Abstracts.
Abstract 5509 - Sex hormone, Insulin and insulin-like growth factors in High stage endometrial cancers
Drs Huang, Bae-Jump
Dr Huang talkng now about sex hormones and insulin in endometrial cancer. GOG 210 . Understanding this is important due to increased dx of endometrial cancers. #ASCO19 #gyncsm pic.twitter.com/fkSlzgKmg3— Dee Sparacio (@womenofteal) June 2, 2019
Dr Jump Bae talking insulin and the IGF pathway role in endometrial cancer. And as a biomarker Abs 5509 #ASCO19 #gyncsm pic.twitter.com/s8mGyjlk20— Dee Sparacio (@womenofteal) June 2, 2019
— Dee Sparacio (@womenofteal) June 2, 2019Abstract 5010 - Phase 2 trial ribociclib and letrozole in ER positive ovarian and endometrial cancers Drs Colon-Otero and Mackay
Dr Colon-Otero talking ribociclib ( cycling kinase inhibitor) and letrozole aromorase inhibitor #ASCO19 #gyncsm all 3 low grade serious OC patients still on trial and progression free pic.twitter.com/sOiM0Yquo0— Dee Sparacio (@womenofteal) June 2, 2019
— Dee Sparacio (@womenofteal) June 2, 2019Abstract 5011 - Phase 2 avelumab plus entinostat or placebo in epithelial ovarian cancer
Drs. Cadoo and Hays
More disappointing results for #immunotherapy in #OvarianCancer- there was no difference in PFS between avelumab with it without entinostat. Response rates were only 5%. ##gyncsm #ASCO19 pic.twitter.com/vbamSQgKAz— Shannon Westin (@ShannonWestin) June 2, 2019
Dr Cardozo ENCOre 603 Avelumab w w/out entinostat in Adv OC ( 3-6 prior therapies) no difference between arms #ASCO19 #gyncsm pic.twitter.com/spWUNUtoQa— Dee Sparacio (@womenofteal) June 2, 2019
— Dee Sparacio (@womenofteal) June 2, 20196/2/2019 Wanna Get Away - Continuous treatment vs Treatment Holidays in Gyn Cancers
Dr Buckanovich - Successful Maintenance?
Wow Buckanovich so much to think about for maintenance chemo, Avastin, PARP busy listening so only one slide #ASCO19 #gyncsm pic.twitter.com/jQ4VG2NouM— Dee Sparacio (@womenofteal) June 2, 2019
Dr Oza - Maintenance Standard of Care
On to the next session Dr Oza looking at endpoints - what do they mean to. Patients #ASCO19 #gyncsm pic.twitter.com/FaPj2WE6Q4— Dee Sparacio (@womenofteal) June 2, 2019
— Dee Sparacio (@womenofteal) June 2, 2019Dr Rustin - Maintenance - Not Ready for Prime Time
Dr. Trent - Sarcoma PerspectiveThen we had Dr Rustin’s presentation on maintenance for OC— Dee Sparacio (@womenofteal) June 2, 2019
Avastin PFS improvement but not OS , same for Parp’s ( at least to date #ASCO19 #gyncsm maybe save for recurrence ? pic.twitter.com/MxoEvVedUh
6/2/2019 Gyn Cancers is it Time to Put Away the Knife?Now @JTrentMDPhD presenting on Gyn Sarcoma #gyncsm #ASCO19 case studies included pic.twitter.com/AYOjaomKMT— Dee Sparacio (@womenofteal) June 2, 2019
For this session I did not have a good view of the screen so here are the high points from my notes.
Dr. Duska - Adv OC -Time to Put Away the Knife?
NACT ( Neoadjuvent chemotherapy) is a viable option for a certain population of patients with ovarian cancer
Dr Pfisterer We need a sharper smarter knife
Residual Tumor is an independent prognostic indicator. The Goal is R0 ( no visible disease left) . What prevents R0 . Factors that influence R0 are Inoperability (sugery not tolerated), Insufficiency (surgeon not capable of performing surgery . Patient survival better when surgery is done by a gyn onc.) Irresectability ( surgery not possible due to location of tumor.)
Dr Ramirez Has Laparoscopy Sung its Final Song in Cervix Cancer
Reported on LACC Study (https://www.nejm.org/doi/full/10.1056/NEJMoa1806395) Study found that radical hysterectomy by MIS (minimally invasive survery ) lead to lower rates of disease free survival compared to open hysterectomy.
Dr Boggess - There is still a Role of MIS in Cervical Cancer
6/3/2019 The More Things Change the Ovarian Cancer Edition
Monk - Is It Time to Change Upfront Chemotherapy For Ovarian Cancer
— Dee Sparacio (@womenofteal) June 3, 2019Dr Randall HIPEC: Standard of Care or Hype
— Dee Sparacio (@womenofteal) June 3, 2019
Randall - the study that lead to NCCN addition for HIPEC . #ASCO19 #gyncsm pic.twitter.com/g3LItoSfia— Dee Sparacio (@womenofteal) June 3, 2019
Dr. Grisham - Low Grade Ovarian Carcinoma: Fitting the Square Peg in the Round Hold
— Dee Sparacio (@womenofteal) June 3, 2019
— Dee Sparacio (@womenofteal) June 3, 2019Tomorrow I will share information from sessions dealing with communication ( Tweets Chats & Posts and Navigating a New Cancer Diagnosis).
Dee
Every Day is a Blessing!
No comments:
Post a Comment